1-15 of 15
P. Chollet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P1-08-34: Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial

Free
J-M Nabholtz, M-A Mouret-Reynier, C Abrial, M-M Dauplat, N Radosevic-Robin, I Van Praagh, V Servent, J-P Jacquin, A-V Bourcier, F Del Piano, P Dubray-Longeras, B Nayl, F Kwiatkoswki, A Cayre, N Uhrhammer, Y Bidet, N Chalabi, Y-J Bignon, P Chollet, F Penault-Llorca
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P1-08-34.
https://doi.org/10.1158/0008-5472.SABCS13-P1-08-34
Published: 15 December 2013
View article titled, Abstract P1-08-34: Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial
Journal Articles

Abstract P3-14-19: Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome

Free
F Penault-Llorca, N Radosevic-Robin, C Abrial, M-M Dauplat, B Weber, M-A Mouret-Reynier, J Gligorov, O Tredan, M Privat, N Uhrhammer, A Desrichard, Y Bidet, A Cayre, C Aube, P Romero, F Kwiatkowski, N Chalabi, Y-J Bignon, P Chollet, J-M Nabholtz
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P3-14-19.
https://doi.org/10.1158/0008-5472.SABCS13-P3-14-19
Published: 15 December 2013
View article titled, Abstract P3-14-19: Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome
Journal Articles

Abstract P3-06-20: Is it possible to predict the efficacy of a combination of Panitumumab plus FEC 100 followed by docetaxel (T) for patients with triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial.

Free
J-M Nabholtz, M-M Dauplat, C Abrial, B Weber, M-A Mouret-Reynier, J Gligorov, O Tredan, L Vanlemmens, T Petit, S Guiu, C Jouannaud, N Tubiana-Mathieu, F Kwiatkowski, A Cayre, N Uhrhammer, M Privat, A Desrichard, P Chollet, N Chalabi, F Penault-Llorca
Journal: Cancer Research
Cancer Res (2012) 72 (24_Supplement): P3-06-20.
https://doi.org/10.1158/0008-5472.SABCS12-P3-06-20
Published: 15 December 2012
View article titled, Abstract P3-06-20: Is it possible to predict the efficacy of a combination of Panitumumab plus FEC 100 followed by docetaxel (T) for patients with triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial.
Journal Articles

P3-14-01: Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.

Free
J-M Nabholtz, B Weber, J Gligorov, M-A Mouret-Reynier, O Tredan, L Vanlemmens, T Petit, F Mayer, Praagh-Doreau I Van, P Dubray-Longeras, B Nayl, J-P Ferriere, C Jouannaud, H Devaud, N Tubiana-Mathieu, C Abrial, F Kwiatkowski, E Planchat, N Chalabi, F Penault-Llorca, P Chollet
Journal: Cancer Research
Cancer Res (2011) 71 (24_Supplement): P3-14-01.
https://doi.org/10.1158/0008-5472.SABCS11-P3-14-01
Published: 15 December 2011
View article titled, P3-14-01: Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.
Journal Articles

P5-14-20: Neoadjuvant Chemotherapy (NCT) in 466 Patients for Operable Breast Cancer: The Prognostic Value of SBR Grade Variation.

Free
C Abrial, M-A Mouret-Reynier, Q Wang-Lopez, X Durando, E Thivat, I Raoelfils, P Gimbergues, Praagh-Doreau I Van, J-M Nabholtz, P Chollet, F Penault-Llorca
Journal: Cancer Research
Cancer Res (2011) 71 (24_Supplement): P5-14-20.
https://doi.org/10.1158/0008-5472.SABCS11-P5-14-20
Published: 15 December 2011
View article titled, P5-14-20: Neoadjuvant Chemotherapy (NCT) in 466 Patients for Operable Breast Cancer: The Prognostic Value of SBR Grade Variation.
Journal Articles

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

Free
B. Coudert, M. Campone, M. Spielmann, M. Symann, F. Eichler, D. Serin, T. Delozier, G. Romieu, J. Canon, H. Orfeuvre, G. Piot, T. Petit, P. Chollet, G. Jerusalem, B. Audhuy, C. Veyret, M. Beauduin, J. Eymard, A. Martin, H. Roché
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 603.
https://doi.org/10.1158/0008-5472.SABCS-09-603
Published: 15 December 2009
View article titled, Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.
Journal Articles

Clinicopathological Factors and Nomograms Predicting Non Sentinel Lymph Nodes Metastases after Neoadjuvant Chemotherapy in Breast Cancer Patients.

Free
P. Gimbergues, C. Abrial, C. Abrial, X. Durando, X. Durando, G. Le Bouëdec, F. Cachin, F. Cachin, F. Penault-Llorca, M. Mouret-Reynier, M. Mouret-Reynier, F. Kwiatkowski, J. Maublant, J. Maublant, J. Maublant, A. Tchirkov, A. Tchirkov, J. Dauplat, P. Chollet, P. Chollet, P. Chollet
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 1011.
https://doi.org/10.1158/0008-5472.SABCS-09-1011
Published: 15 December 2009
View article titled, Clinicopathological Factors and Nomograms Predicting Non Sentinel Lymph Nodes Metastases after Neoadjuvant Chemotherapy in Breast Cancer Patients.
Journal Articles

Sequential FEC 100-Docetaxel (T) Neoadjuvant Chemotherapy (NCT) in Stage II-III Operable Breast Cancer.

Free
P. Dubray, P. Dubray, C. Abrial, C. Abrial, M. Mouret-Reynier, M. Mouret-Reynier, B. Nayl, B. Nayl, E. Thivat, E. Thivat, P. Gimbergues, J. Achard, F. Penault-Llorca, F. Penault-Llorca, P. Chollet, P. Chollet, P. Chollet, P. Chollet, X. Durando, X. Durando, X. Durando
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 1105.
https://doi.org/10.1158/0008-5472.SABCS-09-1105
Published: 15 December 2009
View article titled, Sequential FEC 100-Docetaxel (T) Neoadjuvant Chemotherapy (NCT) in Stage II-III Operable Breast Cancer.
Journal Articles

Post-Operative 5FU-Docetaxel after High-Dose of Pre-Operative Epirubicin-Cyclophosphamide for Treatment of Inflammatory Breast Cancer: Results of the FNCLCC-Pegase 07 Trial.

Free
P. Viens, T. Palangié, J. Ferrero, P. Chollet, T. Bachelot, R. Delva, M. Fabbro, M. Janvier, J. Lotz, C. Linassier, N. Dohollou, J. Eymard, B. Leduc, J. Genève, A. Martin, J. Boher, H. Roché
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 2081.
https://doi.org/10.1158/0008-5472.SABCS-09-2081
Published: 15 December 2009
View article titled, Post-Operative 5FU-Docetaxel after High-Dose of Pre-Operative Epirubicin-Cyclophosphamide for Treatment of Inflammatory Breast Cancer: Results of the FNCLCC-Pegase 07 Trial.
Journal Articles

No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study.

Free
N. Harbeck, A. Chan, D. ten Bokkel Huinink, P. Chollet, D. Gimenes, C. Fabiani, S. Salvagni, L. Pérez-Michel, A. Schneeweiss, A. Chlistalla, D. Miles
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 6086.
https://doi.org/10.1158/0008-5472.SABCS-09-6086
Published: 15 December 2009
View article titled, No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study.
Journal Articles

Weight Variation during Chemotherapy and Breast Cancer Prognostic.

Free
S. Therondel, E. Thivat, O. Lapirot, C. Abrial, P. Gimbergues, E. Planchat, M. Mouret-Reynier, P. Chollet, X. Durando
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 6049.
https://doi.org/10.1158/0008-5472.SABCS-09-6049
Published: 15 December 2009
View article titled, Weight Variation during Chemotherapy and Breast Cancer Prognostic.
Journal Articles

A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer.

Free
J Machiels, P Chollet, A Taleb, J Baurain, Y Humblet, F Mazzeo, K Zaman, F Kasiborski, J Bauer
Journal: Cancer Research
Cancer Res (2009) 69 (2_Supplement): 6124.
https://doi.org/10.1158/0008-5472.SABCS-6124
Published: 15 January 2009
View article titled, A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer.
Journal Articles

Cytotoxic doses of curcuminoids provoke a down-regulation of phospholipid biosynthesis – a focused metabolomic profiling.

Free
M Bayet-Robert, D Morvan, P Chollet, C Barthomeuf
Journal: Cancer Research
Cancer Res (2009) 69 (2_Supplement): 6029.
https://doi.org/10.1158/0008-5472.SABCS-6029
Published: 15 January 2009
View article titled, Cytotoxic doses of curcuminoids provoke a down-regulation of phospholipid biosynthesis – a focused metabolomic profiling.
Journal Articles

Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.

Free
P Gimbergues, C Abrial, G Le Bouedec, F Cachin, F Penault-Llorca, M Mouret-Reynier, F Kwiatkowski, J Maublant, A Tchirkov, J Dauplat, P Chollet, X Durando
Journal: Cancer Research
Cancer Res (2009) 69 (2_Supplement): 1020.
https://doi.org/10.1158/0008-5472.SABCS-1020
Published: 15 January 2009
View article titled, Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Journal Articles

Variations in Committed Stem Cells (CFU-GM and CFU-TL) in the Peripheral Blood of Cancer Patients Treated by Sequential Combination Chemotherapy for Breast Cancer

Free
F. Rusé-Riol, M. Legros, D. Bernard, J. Chassagne, H. Clavel, J. P. Ferriere, P. Chollet, R. Plagne
Journal: Cancer Research
Cancer Res (1984) 44 (5): 2219–2224.
Published: 01 May 1984
View article titled, Variations in Committed Stem Cells (CFU-GM and CFU-TL) in the Peripheral Blood of Cancer Patients Treated by Sequential Combination Chemotherapy for Breast Cancer
Open the PDF for Variations in Committed Stem Cells (CFU-GM and CFU-TL) in the Peripheral Blood of Cancer Patients Treated by Sequential Combination Chemotherapy for Breast Cancer in another window